Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

Question 2

How does KB408 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the study visits involve, and how often will I need to come in?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any side effects I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience a health issue during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

Question 6

Will I need to stop any other medications or treatments while participating?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency clinical trial (NCT06049082). Contact the study team or your healthcare provider for specific answers.

What this study is about